CONNEXIN 43 FOR USE IN THE TREATMENT OF RETINOBLASTOMA PROTEIN POSITIVE TUMOURS

The present invention to connexin 43 (Cx43) for use in the treatment of a type of cancer characterized by the presence of functional retinoblastoma gene (RB), or by the presence of functional RB and also by hyperactivity of CDK4 and CDK6, preferably in combination with a CDK4/6 inhibitor.

Saved in:
Bibliographic Details
Main Authors CARPINTERO FERNÁNDEZ, Paula, ACEA NEBRIL, Benigno, GARCÍA YUSTE, Alejandro, MAYÁN SANTOS, María Dolores, FONSECA CAPDEVILA, Eduardo
Format Patent
LanguageEnglish
French
German
Published 29.05.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention to connexin 43 (Cx43) for use in the treatment of a type of cancer characterized by the presence of functional retinoblastoma gene (RB), or by the presence of functional RB and also by hyperactivity of CDK4 and CDK6, preferably in combination with a CDK4/6 inhibitor.
Bibliography:Application Number: EP20220751728